Clinical observation of combination regimen containing Lobaplatin in treating advanced breast cancer patients

doi:10.3877/cma.j.issn.1674-0793.2016.01.008

Abstract

Abstract:

Objective

To observe the efficacy and toxicity of combination regimen containing Lobaplatin in treatment of advanced breast cancer.

Methods

A total of thirty-three patients with ad-vanced breast cancer were treated with Lobaplatin (30 mg/m²) and another chemotherapeutic drug with twenty-one days as a cycle. The efficacy and side effects were evaluated after at least two cycles of chemo-therapy.

Results

The efficacy and toxicity could be evaluated in all patients with 1 of CR, 11 of PR, 14 of SD and 7 of PD. The response rate was 36.4% and the disease control rate was 78.8%. The median pro-gression-free survival was 6.5 months and the median overall survival was 14 months. The 1-year survival rate was 75.8%. The main side effects were myelosuppression and gastrointestinal reaction and could be well tolerated.

Conclusion

Combination regimen containing Lobaplatin for advanced breast cancer is ef-fective and well tolerated.

Key words: Breast neoplasms, Drug therapy, combination

Luo Zhang, Qing Li, Haifeng Lin, Zhigang Lin. Clinical observation of combination regimen containing Lobaplatin in treating advanced breast cancer patients[J]. Chinese Archives of General Surgery(Electronic Edition), 2016, 10(01): 47-49.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2016.01.008

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2016/V10/I01/47

Figures/Tables 2

References 10

1	Engel JB,Martens T,Hahne JC, et al. Effects of lobaplatin as a single agent and in combination with TRAIL on the growth of tri-ple-negative p53-mutated breast cancers in vitro[J]. Anticancer Drugs, 2012, 23(4): 426-436.
2	张娇,付丽,马勇杰,等.乳腺癌与Slit/Robo信号通路关系的研究进展[J].中华实验外科杂志, 2010, 27(9): 1362-1363.
3	崔世恩,凌飞海,储兵.不同亚型乳腺癌初次转移时间及带瘤生存的研究[J/CD].中华普通外科学文献:电子版, 2013, 7(4): 289-294.
4	宋三泰.晚期乳腺癌如何选择内外科治疗[J].医学与哲学, 2014, 35(8B): 10-11.
5	左丽,徐迎春,陶莉,等.长春瑞滨联合希罗达治疗蒽环类和紫杉类耐药的晚期乳腺癌临床分析[J].中国肿瘤临床, 2012, 39(19): 1443-1445.
6	Xie CY,Xu YP,Jin W, et al. Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer[J]. Anticancer Drug, 2012, 23(7): 698-705.
7	Deng QQ,Huang XE,Ye LH, et al. Phase Ⅱ trial of Loubo(lo-baplatin) and pemetrexed for patients with metastatic breast can-cer not responding to anthracycline or taxanes[J]. Asian Pac J Cancer Prev, 2013, 14(1): 413-417.
8	刘德林,孙蔚莉,武渊,等.含洛铂的联合方案治疗晚期乳腺癌的临床观察[J].临床肿瘤学杂志, 2013, 18(2): 129-132.
9	肖华伍,欧阳取长.洛铂联合卡培他滨治疗22例晚期乳腺癌的临床观察[J].临床肿瘤学杂志, 2013, 18(3): 246-248.
10	郑向欣,管小青,吴骥,等.培美曲塞联合奈达铂治疗晚期乳腺癌的近期疗效[J].中国肿瘤外科杂志, 2014, 6(1): 12-15.

毒性不良反应	0级	1级	2级	3级	4级
白细胞减少	5(15.2)	5(15.2)	12(36.4)	8(24.2)	3(9.1)
血小板减少	16(48.5)	9(27.3)	5(15.2)	2(6.1)	1(3)
贫血	10(30.3)	9(27.3)	9(27.3)	5(15.2)	0(0)
恶心、呕吐	0(0)	10(30.3)	15(45.5)	7(21.2)	1(3)
肝功能损害	18(54.5)	12(36.4)	3(9.1)	0(0)	0(0)
手足综合征	22(66.7)	8(24.2)	3(9.1)	0(0)	0(0)
腹泻	20(60.6)	7(21.2)	4(12.1)	2(6.1)	0(0)
口腔炎	18(54.5)	11(33.3)	4(12.1)	0(0)	0(0)

毒性不良反应	0级	1级	2级	3级	4级
白细胞减少	5(15.2)	5(15.2)	12(36.4)	8(24.2)	3(9.1)
血小板减少	16(48.5)	9(27.3)	5(15.2)	2(6.1)	1(3)
贫血	10(30.3)	9(27.3)	9(27.3)	5(15.2)	0(0)
恶心、呕吐	0(0)	10(30.3)	15(45.5)	7(21.2)	1(3)
肝功能损害	18(54.5)	12(36.4)	3(9.1)	0(0)	0(0)
手足综合征	22(66.7)	8(24.2)	3(9.1)	0(0)	0(0)
腹泻	20(60.6)	7(21.2)	4(12.1)	2(6.1)	0(0)
口腔炎	18(54.5)	11(33.3)	4(12.1)	0(0)	0(0)

[1]	Yaping Jia, Shu'e Zeng. Ultrasound and pathological characteristics of breast metaplastic carcinoma containing squamous cell carcinoma components [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(08): 844-848.
[2]	Wei Tang, Rongquan He, Suning Huang. Application of deep learning in imaging for diagnosis, treatment and prognosis prediction of breast cancer [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(06): 323-328.
[3]	Xia Kang, Hao Tian, Jin Qian, Yuan Gao, Hongming Miao, Xiaowei Qi. Osteorin attenuates osteolysis during bone metastasis of cancers through inhibiting osteoclastogenesis [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(06): 329-339.
[4]	Xiaoli Yi, Shasha Hu, Yan Zhang. Impact of HER-2 low expression on response of neoadjuvant chemotherapy and prognosis in breast cancer patients [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(06): 340-346.
[5]	Jie Shi, Yuntao Li, Haiyan Gao. Prognosis of node-positive luminal A breast cancer patients with neoadjuvant and adjuvant chemotherapy and influencing factors [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(06): 353-361.
[6]	Jiaxuan Liu, Binghe Xu. Annual advancement of clinical research on breast cancer in China [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(05): 259-265.
[7]	Chengcai Yao, Changchun Liu, Wenjian Huang, Ming Chen. Single-port non-lipolysis fluorescence-guided laparoscopy for axillary lymph node biopsy in early breast cancer [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(05): 266-271.
[8]	Bohui Shi, Xiping Ding, Lian Wang, Rong Li, Pingli Guo, Jing Qi, Yao Chen, Na Hao, Yu Ren. Summary of best evidences for prevention and treatment of subcutaneous seroma after breast cancer surgery [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(05): 277-284.
[9]	Yaping Wang, Jing Fan, Niuniu Hou, Rui Ling. Clinical significance of tumor-infiltrating lymphocytes in HER-2-positive early breast cancer [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(04): 203-209.
[10]	Wenbo Gao, Ming Li, Yunhao Zhang. Prognostic value and clinical significance of advanced lung cancer inflammation index in patients with triple negative breast cancer [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(04): 210-217.
[11]	Qinqin Zhang, Junnan Wang, Houmin Lin, Ying Wu, Yuemei Tan, Mingzhou Li, Junfei Jin, Ningxia Wang, Yong Hong. Bioinformatics analysis of differential expression and clinical significance of complement 3 in breast cancer [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(04): 271-277.
[12]	Qingyan Yan, Xiaomei Yong, Hong Luo, Min Du. Prognostic factors and survival analysis of multicenter elderly patients with metastatic breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 636-638.
[13]	Zhiming Li, Chenming Guo, Xiaochen Zhuang, Xueqin Hou, Junxi Gao. Comparative study of qualitative and quantitative indicators of contrast-enhanced ultrasound in early breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 639-643.
[14]	Hongbo Qu, Fang Zhu, Zhe Xu, Nan Wu, Jianhuai He, Xianming Wang. Application of subclavian lymph node dissection through intermuscular approach in locally advanced breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(05): 510-513.
[15]	Shan Chen, Zhiqiang Hu, Yueming Zhang, Ding Tang, Meng Li, Shuai Zhao. Expression of Orai1 and Orai3 in breast cancer and their correlation with pathological indexes [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(05): 514-517.

Please choose a citation manager

Content to export